DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR THE QUANTITATIVE ANALYSIS OF THE SUBSTANCE OF A NEW BIOLOGICALLY ACTIVE COMPOUND 3-[2-OXO-2-(4-PHENYL-1-PIPERAZINYL)ETHYL]-4(3H)-QUINAZOLINONE

The purpose of the work is to study the possibility of using spectrophotometry in the UV region for the quantitative determination of a previously un-studied substance of 3- [2- (4-phenyl-1-piperazino) -2-oxoethyl] -quinazolin-4 (3H) -one (VMA-10 -21), as well as the development and validation of methods for its quantitative determination. Material and methods. In the course of the experiment, the analytical equipment was used: spectrophotometer SF-56, analytical balance RADWAG AS 220/C/2, measuring dishes of the 1st accuracy class. The optical density of the test solutions was measured at a wavelength of 275 nm in cu-vettes with a layer thickness of 10 mm. As a comparison solution used 1% solution of hydrochloric acid. Validation of the presented methodology was carried out according to indicators: linearity, precision and correctness. Processing of the experimental data was carried out according to OFS.1.1.0013.15 GF XIV edition. The specific absorption index was calculated using a standard sample of substance VMA-10-21, the purity of which was proved using the HPLC method. Results. The spectrum of the substance VMA-10-21 in the ultraviolet region was represented by two absorption bands with maxima at wavelengths of 235 and 275 nm. The use of a wavelength at a wavelength of 275 nm is justified. The specific absorption index at the selected wavelength was calcu-lated. A quantitative determination technique has been developed which, according to validation parameters, linearity, precision and correctness com-plies with the requirements of OFS.1.1.0012.15 GF of the XIV edition. Conclusions. The possibility of using spectrophotometry in the UV region for the quantitative determination of the substance VMA-10-21 was studied. A spectrophotometric method for the quantitative determination of the basic substance in the substance VMA-10-21 was developed and validated.